- Report
- June 2026
Germany
From €2220EUR$2,500USD£1,904GBP
- Report
- June 2026
France
From €2220EUR$2,500USD£1,904GBP
- Report
- June 2026
- 100 Pages
Middle East
From €3370EUR$3,795USD£2,890GBP
- Report
- June 2026
- 100 Pages
Global
From €3370EUR$3,795USD£2,890GBP
- Report
- June 2026
- 100 Pages
Africa
From €3370EUR$3,795USD£2,890GBP
- Report
- June 2026
Vietnam
From €2220EUR$2,500USD£1,904GBP
- Report
- June 2026
Russia
From €2220EUR$2,500USD£1,904GBP
- Report
- June 2026
Poland
From €2220EUR$2,500USD£1,904GBP
From €2220EUR$2,500USD£1,904GBP
- Report
- June 2026
Ireland
From €2220EUR$2,500USD£1,904GBP
From €2220EUR$2,500USD£1,904GBP
- Report
- June 2026
Brazil
From €2220EUR$2,500USD£1,904GBP
- Report
- June 2026
Argentina
From €2220EUR$2,500USD£1,904GBP
- Report
- October 2023
- 71 Pages
Global
From €3500EUR$4,223USD£3,107GBP
- Report
- August 2026
- 50 Pages
Global
From €2353EUR$2,650USD£2,018GBP
- Report
- November 2021
- 620 Pages
Global
From €3552EUR$4,000USD£3,046GBP

Valganciclovir is an antiviral drug used to treat infections caused by certain viruses, such as cytomegalovirus (CMV). It is used in the treatment of infectious diseases, including CMV retinitis, a viral infection of the retina that can cause blindness. Valganciclovir is also used to prevent CMV infection in people who have received organ transplants. It works by blocking the action of the virus in the body, preventing it from multiplying and spreading.
Valganciclovir is available in tablet and oral solution form. It is usually taken twice daily, with or without food. Common side effects include nausea, vomiting, diarrhea, and headache. More serious side effects may include kidney problems, anemia, and low white blood cell count.
Valganciclovir is marketed by several pharmaceutical companies, including Genentech, Merck, and Novartis. It is also available as a generic drug. Show Less Read more